Trialkyne Linking Agents and Methods of Use

US2025092072A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025092072-A1
Application numberUS-202418773657-A
CountryUS
Kind codeA1
Filing dateJul 16, 2024
Priority dateFeb 17, 2018
Publication dateMar 20, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

First claim

Opening claim text (preview).

1 - 17 . (canceled) 18 . A compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each independently linkers comprising optionally substituted alkylene; L 4 is a linker comprising optionally substituted alkylene, optionally substituted arylene, and optionally substituted cycloalkylene; each instance of R 1 is optionally substituted alkyl; R 2 is optionally substituted alkyl; and R 4 is H or optionally substituted alkyl. 19 - 24 . (canceled) 25 . A compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each independently linkers comprising optionally substituted alkylene; L 4 is a linker comprising optionally substituted alkylene, optionally substituted arylene, and optionally substituted cycloalkylene; R 4 is H or optionally substituted alkyl; X is O or S; and RNA comprises or consists of an RNAi agent. 26 - 31 . (canceled) 32 . The compound or pharmaceutically acceptable salt thereof of claim 25 , wherein the compound is selected from the group consisting of: Compound No. Structure 1-O-III 1-S-III 2-O-III 2-S-III 3-O-III 3-S-III 4-O-III 4-S-III 5-O-III 5-S-III 6-O-III 6-S-III 7-O-III 7-S-III 8-O-III 8-S-III 9-O-III 9-S-III 10-O-III 10-S-III 11-O-III

Assignees

Inventors

Classifications

  • the bicyclo ring system containing eight carbon atoms · CPC title

  • the bicyclo ring system containing five carbon atoms · CPC title

  • The ring being saturated · CPC title

  • Optical isomers · CPC title

  • Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025092072A1 cover?
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interfere…
Who is the assignee on this patent?
Arrowhead Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification C07F9/2416. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Mar 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).